Objective The optimal sequence of administering chemotherapy (CT) and radiation treatment (RT) in women with node-positive endometrial carcinoma (EC) remains controversial. We used the National Cancer Database to evaluate overall survival (OS) in women with advanced EC receiving different sequences of adjuvant therapy.
Methods The National Cancer Database was queried for female adults with International Federation of Gynecology and Obstetrics 2009 stage IIIC1 to IIIC2 EC diagnosed from 2004 to 2012 treated with hysterectomy and adjuvant CT and RT. Overall survival was compared between sequential treatment (CT followed by RT) and concurrent treatment (CT and RT within 4 weeks). χ2 tests assessed differences by sequence and various clinical variables. Log-rank test and Cox proportional hazards models evaluated OS. Risk factors related to OS were identified by univariate and multivariate analyses.
Results Of 1826 patients, 67% (1218) received sequential treatment and 33% (608) received concurrent treatment. The median follow-up was 49.2 months. The sequential treatment group had a better 5-year OS (67% [95% confidence interval = 64%–70%]) than the concurrent treatment group (62% [95% confidence interval = 57%–66%]) (P = 0.004). On multivariate analysis, the strongest predictors of worse OS were increasing age (hazard ratio [HR] = 1.04 [1.02–1.06], P = 0.0003), type 2 versus type 1 EC (HR = 1.60 [1.06–2.43], P = 0.03), grade 3 versus 1 (HR = 2.64 [1.23–5.67], P = 0.01), residual disease or positive margin versus negative margin (HR = 2.25 [1.43–3.56], P = 0.0005), and concurrent versus sequential treatment (HR = 1.67 [1.15–2.40], P = 0.006).
Conclusions This study suggests that upfront CT followed by RT may be a better treatment sequence for adjuvant therapy in women with advanced EC.
- Endometrial cancer
- Node positive
- Advanced stage
- Radiation treatment
Statistics from Altmetric.com
The authors declare no conflicts of interest.
Accepted for presentation at the 59th Annual Meeting of The American Society of Radiation Oncology (ASTRO), San Diego, California, September 24–27, 2017.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.